http://www.mayoclinicproceedings.org/pb/assets/raw/Health%20Advance/journals/jmcp/jmcp_pr89_5_2.pdf[*QUOTE*]
-------------------------------------------------------------------------------------------------------
For additional news and information, visit: Mayo Clinic News Network.
News Release
Mayo Clinic First to Show Virotherapy is Promising Against Multiple MyelomaROCHESTER, Minn. — April 14, 2014 — In a proof of principle clinical trial, Mayo Clinic researchers
have demonstrated that virotherapy — destroying cancer with a virus that infects and kills cancer cells but spares normal tissues — can be effective against the deadly cancer multiple myeloma. The findings appear in the journal Mayo Clinic Proceedings.
Two patients in the study received a single intravenous dose of an engineered measles virus (MV-NIS) that is selectively toxic to myeloma plasma cells. Both patients responded, showing reduction of both bone marrow cancer and myeloma protein. One patient, a 49-year-old woman, experienced complete remission of myeloma and has been clear of the disease for over six months.
“This is the first study to establish the feasibility of systemic oncolytic virotherapy for disseminated cancer,” says Stephen Russell, M.D., Ph.D., Mayo Clinic hematologist, first author of the paper and co-developer of the therapy. “These patients were not responsive to other therapies and had experienced several recurrences of their disease.”
Multiple myeloma is a cancer of plasma cells in the bone marrow, which also causes skeletal or soft tissue tumors. This cancer usually responds to immune system-stimulating drugs, but eventually overcomes them and is rarely cured.
In their article, the researchers explain they were reporting on these two patients because they were the first two studied at the highest possible dose, had limited previous exposure to measles, and therefore fewer antibodies to the virus, and essentially had no remaining treatment options.
Oncolytic virotherapy – using re-engineered viruses to fight cancer – has a history dating back to the 1950s.
Thousands of cancer patients have been treated with oncolytic viruses from many different virus families (herpesviruses, poxviruses, common cold viruses, etc.). However, this study provides the first well-documented case of a patient with disseminated cancer having a complete remission at all disease sites after virus administration.
The second patient in the paper, whose cancer did not respond as well to the virus treatment, was equally remarkable because her imaging studies provided a clear proof that the intravenously administered virus specifically targeted the sites of tumor growth. This was done using high-tech imaging studies, which were possible only because the virus had been engineered with a 'snitch gene' — an easily identifiable marker — so researchers could accurately determine its location in the body.More of the MV-NIS therapy is being manufactured for a larger, phase 2 clinical trial. The researchers also want to test the effectiveness of the virotherapy in combination with radioactive therapy (iodine-131) in a future study.
Other authors include
Mark Federspiel, Ph.D.,
Kah-Whye Peng, Ph.D., M.Med.,
Caili Tong,
David Dingli,M.D., Ph.D.,
William Morice, M.D., Ph.D.,
Val Lowe, M.D.,
Michael O’Connor, Ph.D.,
Robert Kyle, M.D.,
Nelson Leung, M.D.,
Francis Buadi, M.D.,
S. Vincent Rajkumar, M.D.,
Morie Gertz, M.D.,
Martha Lacy, M.D.,
and senior and corresponding author Angela Dispenzieri, M.D.,
all of Mayo Clinic.
The research was supported by the National Institutes of Health-National Cancer Institute, Al and Mary Agnes McQuinn, The Harold W. Siebens Foundation; and The Richard M. Schulze Family Foundation.
Drs. Russell, Federspiel and Peng and Mayo Clinic have a financial interest in the technology used in the study.
###
About Mayo Clinic
Recognizing 150 years of serving humanity in 2014, Mayo Clinic is a nonprofit worldwide leader in
medical care, research and education for people from all walks of life. For more information, visit
150years.mayoclinic.org,
www.mayoclinic.org and newsnetwork.mayoclinic.org.
MEDIA CONTACT:
Robert Nellis,
Mayo Clinic Public Affairs,
507-284-5005,
newsbureau@mayo.edu
Postal Address:
13400 E. Shea Blvd.
Scottsdale, AZ 85259
200 First Street SW
Rochester, MN 55905
4500 San Pablo Road
Jacksonville, FL 32224
-------------------------------------------------------------------------------------------------------
[*/QUOTE*]
Abstract:
http://www.mayoclinicproceedings.org/article/S0025-6196(14)00368-1/abstract[*QUOTE*]
-------------------------------------------------------------------------------------------------------
Taming Measles Virus to Create an Effective Cancer TherapeuticJohn C. Bell, PhD, FRSC
Centre for Innovative Cancer Research, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada K1H8L6
Published Online: May 13, 2014
DOI:
http://dx.doi.org/10.1016/j.mayocp.2014.04.009Publication stage: In Press Corrected Proof
AbstractFull Text
References
Measles virus (MV) has been a longtime bane of the human race. Once described by Rhazes (10th century Persian physician) as “more dreaded than smallpox,”1 it remains globally one of the leading causes of death among young children.2 In the 5 years before the introduction of the 1963 measles vaccination program, there were over 4 million cases of measles reported in the United States, and nearly twice as many deaths were attributed to measles as to polio infections during that same period.3 Yet for all the misery MV has caused and continues to inflict on mankind, it now appears that a genetically engineered version of the virus may be on its way to becoming an effective treatment for another deadly human malady, late-stage incurable myeloma.
See also page XXX
© 2014 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.
-------------------------------------------------------------------------------------------------------
[*/QUOTE*]
more:
Full text:
http://www.mayoclinicproceedings.org/article/S0025-6196(14)00368-1/fulltextBILD weiß es jetzt auch:
[*QUOTE*]
-------------------------------------------------------------------------------------------------------
Medizin-Sensation!Mega-Dosis Masernviren heilt Krebskranke
Experte Prof. Dr. Ulrich Lauer im Skype-Interview
Masern gegen Krebs: Ein Expertengspräch
Masernviren gegen Krebs Experten-Gespräch mit Virologe Prof. Lauer
Quelle: BILD.TV
16.05.2014 - 18:46 Uhr
Von EMIL RENNERT
Eine Medizin-Sensation aus den USA lässt Ärzte weltweit aufhorchen: Medizinern der Mayo Clinic in Rochester (US-Staat Minnesota) ist es gelungen, eine vermeintlich unheilbar an Krebs erkrankte Frau mit Hilfe einer Mega-Dosis Masern-Viren zu heilen.
-------------------------------------------------------------------------------------------------------
[*/QUOTE*]
mehr:
http://www.bild.de/ratgeber/gesundheit/krebs/masern-viren-zerstoeren-krebszellen-experteninterview-video-36001150.bild.html
Autor
Thema: Massive virus attack against cancer successful! (Gelesen 1464 mal)